Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 24Terminated 13Recruiting 6Withdrawn 3Active not recruiting 3Unknown 1No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × capmatinib × Clear all
NCT03693339 2018-10-03

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Asan Medical Center

Phase 2 Unknown
27 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡